Sangamo Therapeutics (SGMO) Receivables - Net (2016 - 2025)
Sangamo Therapeutics has reported Receivables - Net over the past 16 years, most recently at $400000.0 for Q4 2025.
- Quarterly results put Receivables - Net at $400000.0 for Q4 2025, down 23.95% from a year ago — trailing twelve months through Dec 2025 was $400000.0 (down 23.95% YoY), and the annual figure for FY2025 was $400000.0, down 23.95%.
- Receivables - Net for Q4 2025 was $400000.0 at Sangamo Therapeutics, down from $523000.0 in the prior quarter.
- Over the last five years, Receivables - Net for SGMO hit a ceiling of $10.5 million in Q3 2024 and a floor of $366000.0 in Q1 2025.
- Median Receivables - Net over the past 5 years was $3.2 million (2022), compared with a mean of $3.7 million.
- Biggest five-year swings in Receivables - Net: skyrocketed 814.29% in 2024 and later plummeted 95.02% in 2025.
- Sangamo Therapeutics' Receivables - Net stood at $6.0 million in 2021, then plummeted by 38.47% to $3.7 million in 2022, then crashed by 75.05% to $923000.0 in 2023, then plummeted by 43.01% to $526000.0 in 2024, then fell by 23.95% to $400000.0 in 2025.
- The last three reported values for Receivables - Net were $400000.0 (Q4 2025), $523000.0 (Q3 2025), and $372000.0 (Q2 2025) per Business Quant data.